Effectiveness of rotavirus vaccines in preventing cases and hospitalizations due to rotavirus gastroenteritis in Navarre, Spain

Vaccine

Volumn 30, Issue 3, 2012, Pages 539-543

  Castilla, Jesús ^a,b   Beristain, Xabier ^c   Martínez Artola, Víctor ^c   Navascués, Ana ^d   García Cenoz, Manuel ^a,b   Álvarez, Nerea ^e   Polo, Isabel ^c   Mazón, Ana ^c   Gil Setas, Alberto ^c   Barricarte, Aurelio ^a,b  

^a INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c Universidad Pública de Navarra   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^e Unidad de Patología Crónica Compleja Servicio de Pediatría y Áreas Específicas Hospital Universitario de Navarra Servicio Navarro de Salud Osasunbidea   (Spain)

Author keywords

Case control studies; Hospitalization; Rotavirus; Spain; Vaccine

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; CASE CONTROL STUDY; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG EFFICACY; FECES ANALYSIS; FEMALE; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPHYLAXIS; ROTAVIRUS GASTROENTERITIS; SPAIN; VIRAL GASTROENTERITIS;

CASE-CONTROL STUDIES; CHILD, PRESCHOOL; FECES; FEMALE; GASTROENTERITIS; HOSPITALIZATION; HUMANS; INFANT; MALE; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; SPAIN;

EID: 84355166386     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.11.071     Document Type: Article

References (29)

1. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9:565-572.
2. Charles M.D., Holman R.C., Curns A.T., Parashar U.D., Glass R.I., Bresee J.S. Hospitalizations associated with rotavirus gastroenteritis in the United States, 1993-2002. Pediatr Infect Dis J 2006, 25:489-493.
3. Soriano-Gabarró M., Mrukowicz J., Vesikari T., Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006, 25:S7-S11.
4. Ryan M.J., Ramsay M., Brown D., Gay N.J., Farrington C.P., Wall P.G. Hospital admissions attributable to rotavirus infection in England and Wales. J Infect Dis 1996, 174(Suppl. 1):S12-S18.
5. Fourquet F., Desenclos J.C., Maurage C., Baron S. Acute gastro-enteritis in children in France: estimates of disease burden through national hospital discharge data. Arch Pediatr 2003, 10:861-868.
6. Harris J.P., Jit M., Cooper D., Edmunds W.J. Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease. Vaccine 2007, 25(20):3962-3970.
7. Luquero Alcalde F.J., Eiros Bouza J.M., Rubio A.P., Bachiller Luque M.R., Castrodeza Sanz J.J., Ortiz de Lejarazu Leonardo R. Gastroenteritis by rotavirus in Spanish children. Analysis of the disease burden. Eur J Pediatr 2008, 167:549-555.
8. Ruiz-Palacios G.M., Pérez-Schael I., Velázquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
9. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354:23-33.
10. Wang F.T., Mast T.C., Glass R.J., Loughlin J., Seeger J.D. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. Pediatrics 2010, 125:e208-e213.
11. World Health Organization Rotavirus vaccines: an update. Wkly Epidemiol Record 2009, 84:533-537.
12. Nohynek H., Salo H., Renko M., Leino T. Finland introduces rotavirus vaccine into the national vaccination programme in September 2009. Euro Surveill 2009, 14(35). pii:19322.
13. Paulke-Korinek M., Rendi-Wagner P., Kundi M., Kronik R., Kollaritsch H. Universal mass vaccination against rotavirus gastroenteritis: impact on hospitalization rates in Austrian children. Pediatr Infect Dis J 2010, 29:319-323.
14. Hanquet G., Ducoffre G., Vergison A., Neels P., Sabbe M., Van Damme P., et al. Impact of rotavirus vaccination on laboratory confirmed cases in Belgium. Vaccine 2011, 29:4698-4703.
15. Clark H.F., Lawley D., Mallette L.A., DiNubile M.J., Hodinka R.L. Decline in cases of rotavirus gastroenteritis presenting to the Children's Hospital of Philadelphia after introduction of a pentavalent rotavirus vaccine. Clin Vaccine Immunol 2009, 16:382-386.
16. Tate J.E., Panozzo C.A., Payne D.C., Patel M.M., Cortese M.M., Fowlkes A.L., et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 2009, 124:465-471.
17. Boom J.A., Tate J.E., Sahni L.C., Rench M.A., Hull J.J., Gentsch J.R., et al. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States. Pediatrics 2010, 125(2):e199-e207.
18. de Palma O., Cruz L., Ramos H., de Baires A., Villatoro N., Pastor D., et al. Effectiveness of rotavirus vaccination against childhood diarrhoea in El Salvador: case-control study. BMJ 2010, 340:c2825.
19. Martinón-Torres F., Alejandro M.B., Collazo L.R., Lastres J.M., Díaz S.P., Pillado M.T., et al. Effectiveness of rotavirus vaccination in Spain. Hum Vaccine 2011, 7:757-761.
20. Desai S.N., Esposito D.B., Shapiro E.D., Dennehy P.H., Vázquez M. Effectiveness of rotavirus vaccine in preventing hospitalization due to rotavirus gastroenteritis in young children in Connecticut, USA. Vaccine 2010, 28:7501-7506.
21. Correia J.B., Patel M.M., Nakagomi O., Montenegro F.M., Germano E.M., Correia N.B., et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 2010, 201:363-369.
22. Muhsen K., Chodick G., Goren S., Shalev V., Cohen D. The uptake of rotavirus vaccine and its effectiveness in preventing acute gastroenteritis in the community. Vaccine 2010, 29:91-94.
23. Snelling T.L., Andrews R.M., Kirkwood C.D., Culvenor S., Carapetis J.R. Case-control evaluation of the effectiveness of the G1P[8] human rotavirus vaccine during an outbreak of rotavirus G2P[4] infection in central Australia. Clin Infect Dis 2011, 52:191-199.
24. Kuehn B.M. FDA: benefits of rotavirus vaccination outweigh potential contamination risk. JAMA 2010, 304:30-31.
25. Alejandro M.B., Domingo J.D., Martinón-Torres F. Circovirus and impact of temporary withdrawal of rotavirus vaccines in Spain. Hum Vaccine 2011, 7:798-799.
26. Bishop R.F., Barnes G.L., Cipriani E., Lund J.S. Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 1983, 309:72-76.
27. Velázquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996, 335:1022-1028.
28. Gladstone B.P., Ramani S., Mukhopadhya I., Muliyil J., Sarkar R., Rehman A.M., et al. Protective effect of natural rotavirus infection in an Indian birth cohort. N Engl J Med 2011, 365:337-346.
29. Hull J.J., Teel E.N., Kerin T.K., Freeman M.M., Esona M.D., Gentsch J.R., et al. United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr Infect Dis J 2011, 30(Suppl. 1):S42-S47.